Effects of GLP-1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta-analysis based on randomized controlled trials.

PubMed1 Apr 2026·Diabetes, obesity & metabolism● 6/10i

Effects of GLP-1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta-analysis based on randomized controlled trials.

Wan S, Yan H, Sun QY, Zhu JQ, Wang HH et al.

GLP-1 receptor agonists improved cognitive function scores by 1.33 points on MMSE and 1.70 points on MoCA versus placebo in adults with type 2 diabetes. Meta-analysis of 18 RCTs, 11,114 patients. This provides first pooled RCT evidence that GLP-1RAs may protect against diabetes-related cognitive decline, potentially expanding their therapeutic positioning beyond glucose control. High heterogeneity (I2 = 82-96%) limits confidence in the effect size.

Strategic signal

FDA and EMA will scrutinize cognitive benefit claims given limited precedent for diabetes drugs improving cognition. Novo and Lilly can leverage this for medical affairs positioning with neurologists and geriatricians treating patients with diabetes. CMS coverage discussions may incorporate cognitive benefits as additional value, particularly for Medicare Advantage plans managing dual diabetes-dementia risk populations.

GLP-1Type 2 diabetesBrain/Neuro

Original Abstract

AIMS: Patients with type 2 diabetes mellitus (T2DM) have a significantly increased risk of cognitive impairment, and the protective effects of traditional hypoglycaemic drugs on cognitive function remain unclear. This study systematically evaluated the neuroprotective effects of GLP-1 receptor agonists (GLP-1RAs) based on randomized controlled trial (RCT) evidence, aiming to provide key evidence-based insights for optimizing diabetes management strategies. MATERIALS AND METHODS: A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang, and ClinicalTrials.gov databases to identify studies investigating the impact of GLP-1RAs on cognitive function in T2DM patients, with the search timeframe extending up to July 2025. The analysis focused on RCTs comparing the effects of GLP-1RAs versus placebo (or conventional therapy) on neurocognitive function in T2DM patients. RESULTS: Based on the inclusion criteria, 18 RCTs involving 11 114 participants were included in the primary meta-analysis. Pooled results demonstrated that, compared to the placebo group, GLP-1RA treatment significantly increased Mini-Mental State Examination (MMSE) scores by a weighted mean difference (WMD) of 1.33 (95% CI: 0.67-1.99; I2 = 82%) and Montreal Cognitive Assessment (MoCA) scores by a WMD of 1.70 (95% CI: 0.83-2.56; I2 = 96%). The effect size on MMSE was significantly greater with long-term GLP-1RA use (≥24 weeks) compared to short-term use (<24 weeks) (mean difference = 3.74; t = 6.52, df = 269, p < 0.0001; Cohen's d = 0.79). Sensitivity analyses yielded results closely aligned with the primary analysis, indicating robust stability. Jadad scale assessment confirmed that all included studies achieved a score ≥3. CONCLUSIONS: Current evidence indicates that GLP-1 RA-based therapy may improve cognitive function in patients with type 2 diabetes mellitus compared with placebo. Furthermore, long-term administration or early initiation of GLP-1 RA treatment may offer greater cognitive benefits.

View original source ↗

Related signals

FDA1 Apr 2026·New Drug Approval (NDA/BLA)● 10/10iHigh impact

FDA Approves Foundayo (Orforglipron) — New Drug Approval (NDA/BLA)

FDA approved orforglipron (Foundayo, Eli Lilly) for type 2 diabetes -- a once-daily oral small-molecule GLP-1 receptor agonist. Orforglipron is the first non-peptide oral GLP-1 approved in the US; oral semaglutide (Rybelsus, Novo Nordisk) has been approved for T2D since 2019 and expanded to obesity in January 2026. Unlike Rybelsus, orforglipron requires no fasting or water volume restrictions before dosing.

GLP-1Type 2 diabetesPricing/accessEli Lilly Novo Nordisk

ClinicalTrials19 Mar 2026·Phase 3● 9/10iHigh impact

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Phase 3 SURMOUNT-1 tests once-weekly tirzepatide at three doses versus placebo in adults without type 2 diabetes who have obesity or are overweight with comorbidities. The randomized, double-blind trial targets 2,539 participants with primary efficacy assessment at 72 weeks. This represents tirzepatide's pivotal obesity trial against placebo, potentially supporting Eli Lilly's bid to compete directly with Wegovy in the non-diabetic obesity market. A prediabetes subgroup continues long-term to assess diabetes prevention.

Weight lossGLP-1Eli Lilly

ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impactPick of the week

The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis

Phase 3 trial evaluates semaglutide versus placebo in adults with non-cirrhotic NASH, measuring steatohepatitis resolution, fibrosis improvement, and cirrhosis-free survival over approximately 5 years. The study enrolled 1,205 adults and is active but not recruiting, with completion expected in 2029. This represents Novo Nordisk's push into NASH, a major unmet need with no approved GLP-1 therapies despite strong preclinical rationale. The trial's dual primary endpoints and 5-year duration suggest preparation for a pivotal regulatory filing in this large addressable market.

GLP-1Liver/NASHNovo Nordisk

ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Phase 3 trial evaluating retatrutide for chronic low back pain in people with obesity or overweight, targeting dual primary endpoints of pain intensity reduction and weight loss. 586-person placebo-controlled study expected to complete September 2027, investigating a novel indication beyond traditional metabolic endpoints. Eli Lilly is exploring pain management as a potential expansion for their triple agonist, representing the first major trial of a GLP-1-based therapy specifically for chronic pain conditions.

GLP-1Weight lossOtherEli Lilly